Treatment of transplanted CT26 tumour with dendritic cell vaccine in combination with blockade of vascular endothelial growth factor receptor 2 and CTLA-4.

TY - JOUR

T1 - Treatment of transplanted CT26 tumour with dendritic cell vaccine in combination with blockade of vascular endothelial growth factor receptor 2 and CTLA-4.

AU - Pedersen, Anders Elm

AU - Buus, S

AU - Claesson, M H

N1 - Keywords: Animals; Antigens, CD; Antigens, Differentiation; Colonic Neoplasms; Combined Modality Therapy; Dendritic Cells; Epitopes, T-Lymphocyte; Female; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; T-Lymphocytes, Cytotoxic; Vaccination; Vaccines; Vascular Endothelial Growth Factor Receptor-2

PY - 2005

Y1 - 2005

N2 - We investigated the anti CT26 tumour effect of dendritic cell based vaccination with the MuLV gp70 envelope protein-derived peptides AH1 and p320-333. Vaccination lead to generation of AH1 specific cytotoxic lymphocytes (CTL) and some decrease in tumour growth of simultaneously inoculated CT26 cells. After combination with an antibody against VEGF receptor 2 (DC101), a significant increase in survival of the tumour cell recipients was observed. Also, monotherapy with an antibody against CTLA-4 (9H10), led to approximately 100% survival of tumour cell recipients. However, effective treatment of mice with already established tumours was only obtained after combination of vaccination, DC101 and 9H10 treatment in which setting 80% of the mice rejected their tumours.

AB - We investigated the anti CT26 tumour effect of dendritic cell based vaccination with the MuLV gp70 envelope protein-derived peptides AH1 and p320-333. Vaccination lead to generation of AH1 specific cytotoxic lymphocytes (CTL) and some decrease in tumour growth of simultaneously inoculated CT26 cells. After combination with an antibody against VEGF receptor 2 (DC101), a significant increase in survival of the tumour cell recipients was observed. Also, monotherapy with an antibody against CTLA-4 (9H10), led to approximately 100% survival of tumour cell recipients. However, effective treatment of mice with already established tumours was only obtained after combination of vaccination, DC101 and 9H10 treatment in which setting 80% of the mice rejected their tumours.

U2 - 10.1016/j.canlet.2005.04.012

DO - 10.1016/j.canlet.2005.04.012

M3 - Journal article

C2 - 15927356

SN - 0304-3835

VL - 235

SP - 229

EP - 238

JO - Cancer Letters

JF - Cancer Letters

IS - 2

ER -